Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse

Behavioural Brain Research

Volumn 231, Issue 1, 2012, Pages 217-225

  Enman, Nicole M ^a   Unterwald, Ellen M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; GSK3; Hyperactivity; Sensitization

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; AMPHETAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FRONTAL CORTEX; HYPERACTIVITY; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; SENSITIZATION; STEREOTYPY;

AMPHETAMINE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; GLYCOGEN SYNTHASE KINASE 3; HYPERKINESIS; INDOLES; MALE; MALEIMIDES; MICE; MOTOR ACTIVITY; PHOSPHORYLATION; STEREOTYPED BEHAVIOR;

EID: 84859917137     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.03.027     Document Type: Article

References (39)

1. Sulzer D., Maidment N.T., Amphetamine Rayport S. Other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. Journal of Neurochemistry 1993, 60:527-535.
2. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. The Journal of Neuroscience 1995, 15:4102-4108.
3. Le Moal M., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiological Reviews 1991, 71:155-234.
4. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends in Pharmacological Sciences 1992, 13:177-184.
5. Leith N.J., Kuczenski R. Two dissociable components of behavioral sensitization following repeated amphetamine administration. Psychopharmacology 1982, 76:310-315.
6. Paulson P.E., Camp D.M., Robinson T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991, 103:104-141.
7. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews 1993, 18:247-291.
8. Beaulieu J-M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annual Review of Pharmacology and Toxicology 2009, 49:327-347.
9. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Current Drug Targets 2006, 7:1421-1434.
10. Beaulieu J-M., Sotnikova T.D., Yao W-D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:5099-5104.
11. Miller J.S., Tallarida R.J., Unterwald E.M. Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 2009, 56:1116-1123.
12. Xu C.-M., Wang J., Wu P., Zhu W.-L., Li Q.-Q., Xue Y.-X., et al. Glycogen synthase kinase 3β in the nucleus accumbens core mediates cocaine-induced behavioral sensitization. Journal of Neurochemistry 2009, 111:1357-1368.
13. Xu C.-M., Wang J., Wu P., Xue Y.-X., Zhu W.-L., Li Q.-Q., et al. Glycogen synthase kinase 3β in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization. Journal of Neurochemistry 2011, 12:6-39.
14. Sanberg P.R., Moran T.H., Kubos K.L., Coyle J.T. Automated measurement of stereotypic behavior in rats. Behavioral Neuroscience 1983, 97:830-832.
15. Sanberg P.R., Zoloty S.A., Willis R., Ticarich C.D., Rhoads K., Nagy R.P., et al. Digiscan activity: automated measurement of thigmotactic and stereotypic behavior in rats. Pharmacology Biochemistry and Behavior 1987, 27:569-572.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
17. Dahlstrom A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. Acta Physiologica Scandinavica 1964, 62:1-55.
18. Fallon J.H., Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. Journal of Comparative Neurology 1978, 1:545-580.
19. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000, 96:451-474.
20. Lindvall O. Dopamine pathways in the rat brain. The neurobiology of dopamine 1979, 319-342. Academic Press, London. A.S. Horn, J. Korf, B.H.C. Westerink (Eds.).
21. Ren J., Xu H., Choi J-K., Jenkins B.G., Chen Y.I. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses. Synapse 2009, 63:764-772.
22. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Research 1975, 94:507-522.
23. Creese I., Iversen S.D. The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat. Psychopharmacology 1974, 39:345-357.
24. Joyce E.M., Stinus L., Iversen S.D. Effect of injections of 6-OHDA into either nucleus accumbens septi or frontal cortex on spontaneous and drug-induced activity. Neuropharmacology 1983, 22:1141-1145.
25. Clarke P., Jakubovic A., Fibiger H. Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions of d-amphetamine and apomorphine. Psychopharmacology 1988, 96:511-520.
26. Arnsten A.F.T. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006, 2376-2383.
27. Haddad P.M., Das A., Ashfaq M., Wieck A. A review of valproate in psychiatric practice. Expert Opinion on Drug Metabolism & Toxicology 2009, 5:539-551.
28. Miller J.S., Tallarida R.J., Unterwald E.M. Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice. Brain Research Bulletin 2010, 82:184-187.
29. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., et al. Transgenic mice overexpressing glycogen synthase kinase 3 beta: a putative model of hyperactivity and mania. The Journal of Neuroscience 2006, 26:9022-9029.
30. Ackermann T.F., Kemple D.S., Lang F., Lang U.E. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK3). Cellular Physiology and Biochemistry 2010, 25:775-786.
31. Yang P., Beasley A., Eckermann K., Swann A., Dafny N. Valproate prevents the induction of sensitization to methylphenidate (ritalin) in rats. Brain Research 2000, 887:276-284.
32. Yang P., Beasley A., Swann A., Dafny N. Valproate modulates the expression of methylphenidate (ritalin) sensitization. Brain Research 2000, 874:216-220.
33. Li J.-X., Han R., Deng Y.-P., Chen S.-Q., Liang J.-H. Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behavioral Brain Research 2005, 161:125-132.
34. Monti B., Polazzi E., Contestabile A. Biochemical, molecular, and epigenetic mechanisms of valproic acid neuroprotection. Current Molecular Pharmacology 2009, 2:95-109.
35. Bartoletti M., Gubellini C., Ricci F., Gaiardi M. The GABAB agonist baclofen blocks the expression of sensitisation to the locomotor stimulant effect of amphetamine. Behavioral Pharmacology 2004, 15:397-401.
36. Bartoletti M., Gubellini C., Ricci F., Gaiardi M. Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine. Behavioral Pharmacology 2005, 16:553-558.
37. Frankowska M., Nowak E., Flip M. Effects of GABAB receptor agonists on cocaine hyperlocomotor and sensitizing effects in rats. Pharmacological Reports 2009, 61:1042-1049.
38. Renthal W., Nestler E.J. Epigenetic mechanisms in drug addiction. Trends in Molecular Medicine 2008, 14:341-350.
39. Sanchis-Segura C., Lopez-Atalaya J.P., Barco A. Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition. Neuropsychopharmacology 2009, 34:2642-2654.